Cannabis Use Disorder: Recognition, Risk Factors, and Treatment Options
A clinical guide to diagnosing and treating problematic cannabis use — including what actually works
Cannabis use disorder (CUD) affects approximately 9% of people who ever use cannabis — rising to 17% for adolescent-onset users and 25–50% for daily users. This clinical review covers DSM-5 diagnostic criteria, risk factors, withdrawal management, and the evidence for behavioral and pharmacological treatments.
Defining Cannabis Use Disorder
Cannabis use disorder (CUD) is a recognized clinical diagnosis in DSM-5, defined by a problematic pattern of cannabis use leading to significant impairment or distress. The DSM-5 criteria include 11 symptoms across four domains: impaired control (using more than intended, unsuccessful attempts to cut down, spending significant time obtaining/using cannabis, craving); social impairment (failure to fulfill role obligations, continued use despite social problems, giving up activities); risky use (use in hazardous situations, continued use despite physical/psychological problems); and pharmacological criteria (tolerance, withdrawal).
CUD is diagnosed as mild (2–3 criteria), moderate (4–5 criteria), or severe (6+ criteria). The severity classification has clinical utility: mild CUD may respond to brief intervention, while severe CUD typically requires more intensive treatment. The diagnosis requires that symptoms cause clinically significant impairment — not merely heavy use.
Who Is at Risk?
Risk factors for CUD are well-characterized. The most important are: age of onset (adolescent-onset users have 17% lifetime CUD risk vs. 9% for adult-onset); frequency of use (daily users have 25–50% CUD risk); potency of cannabis used (higher THC content associated with higher CUD risk); genetic factors (heritability of CUD is estimated at 50–70%); and comorbid psychiatric conditions (anxiety, depression, PTSD, ADHD all increase CUD risk).
The relationship between CUD and psychiatric comorbidity is bidirectional: psychiatric conditions increase cannabis use as self-medication, and cannabis use worsens psychiatric conditions. This creates a clinical challenge — treating CUD without addressing the underlying psychiatric condition is associated with high relapse rates, while treating the psychiatric condition without addressing cannabis use is often ineffective.
Cannabis Withdrawal Syndrome
Cannabis withdrawal syndrome (CWS) is recognized in DSM-5 and occurs in approximately 47% of regular users who stop abruptly. Symptoms begin 24–72 hours after cessation, peak at days 2–6, and typically resolve within 2–3 weeks. The most common symptoms are irritability, anxiety, and agitation (present in ~75% of cases), followed by sleep disturbance, decreased appetite, restlessness, and depressed mood. Physical symptoms — headache, sweating, chills, stomach pain — occur in a minority of patients.
CWS is rarely medically dangerous, but it is a major driver of relapse. The return of sleep disturbance and anxiety during withdrawal is particularly challenging for patients who were using cannabis to manage these symptoms. Clinicians should anticipate and proactively manage withdrawal symptoms, particularly sleep disruption, to improve treatment retention.
Behavioral Treatments: What the Evidence Shows
Behavioral treatments are the first-line evidence-based interventions for CUD. Cognitive-behavioral therapy (CBT) has the strongest evidence base: a 2009 meta-analysis found CBT produced significant reductions in cannabis use and CUD symptoms, with effects maintained at 12-month follow-up. Motivational enhancement therapy (MET) — which uses motivational interviewing techniques to enhance intrinsic motivation for change — is effective as a brief intervention (1–4 sessions) for mild-to-moderate CUD.
Combined MET/CBT (the "MET+CBT" protocol) has been the most studied approach in large RCTs, including the Marijuana Treatment Project (n=450). This protocol typically involves 9 sessions over 12 weeks and produces abstinence rates of 15–30% at 12 months — modest but clinically meaningful. Contingency management (providing tangible rewards for cannabis-negative urine tests) significantly improves outcomes when added to CBT, particularly in adolescents.
Pharmacological Treatments: The Evidence Gap
No pharmacological treatment is FDA-approved specifically for CUD — a significant gap given the prevalence of the condition. Multiple agents have been studied in RCTs with mixed results. N-acetylcysteine (NAC): a 2012 RCT found NAC 1,200mg twice daily significantly increased cannabis abstinence in adolescents vs. placebo, but a 2017 adult trial found no significant effect. Gabapentin: a 2012 pilot RCT found gabapentin 1,200mg/day reduced cannabis use and withdrawal symptoms. Zolpidem: improves sleep during withdrawal but does not reduce cannabis use. CBD: a 2019 RCT found CBD 400–800mg/day reduced cannabis use in treatment-seeking adults. Dronabinol (synthetic THC): reduces withdrawal symptoms but does not improve abstinence rates.
The most promising pharmacological approach may be targeting the withdrawal syndrome specifically — using medications to manage irritability, sleep disruption, and anxiety during the critical first 2–3 weeks of abstinence, when relapse risk is highest.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making treatment decisions. See our editorial standards.